28186998|t|Somatic molecular subtyping of prostate tumors from HOXB13 G84E carriers
28186998|a|A recurrent germline mutation (G84E) in the HOXB13 gene is associated with early onset and family history -positive prostate cancer in patients of European descent, occurring in up to 5% of prostate cancer families. To date, the molecular features of prostate tumors occurring in HOXB13 G84E carriers have not been studied in a large cohort of patients. We identified 101 heterozygous carriers of G84E who underwent radical prostatectomy for prostate cancer between 1985 and 2011 and matched these men by race, age and tumor grade to 99 HOXB13 wild-type controls. Immunostaining for HOXB13, PTEN, ERG, p53 and SPINK1 as well as RNA in situ hybridization for ETV1 / 4 / 5 were performed using genetically validated assays. Tumors from G84E carriers generally expressed HOXB13 protein at a level comparable to benign and wild-type glands. ETS gene expression (either ERG or ETV1 / 4 / 5) was seen in 36% (36/101) of tumors from G84E carriers compared to 68% (65/96) of the controls (p < 0.0001). PTEN was lost in 11% (11/101) of G84E carriers compared to 25% (25/99) of the controls (p = 0.014). PTEN loss was enriched among ERG - positive compared to ERG - negative tumors in both groups of patients. Nuclear accumulation of the p53 protein, indicative of underlying TP53 missense mutations, was uncommon in both groups, occurring in 1% (1/101) of the G84E carriers versus 2% (2/92) of the controls (p = NS). Taken together, these data suggest that genes other than ERG and PTEN may drive carcinogenesis / progression in the majority of men with germline HOXB13 mutations.
28186998	8	27	molecular subtyping	T058	UMLS:C0022885
28186998	31	46	prostate tumors	T038	UMLS:C0033578
28186998	52	58	HOXB13	T017	UMLS:C1415664
28186998	59	72	G84E carriers	T038	UMLS:C0206530
28186998	85	109	germline mutation (G84E)	T038	UMLS:C0206530
28186998	117	128	HOXB13 gene	T017	UMLS:C1415664
28186998	148	159	early onset	T033	UMLS:C1833334
28186998	164	178	family history	T033	UMLS:C0241889
28186998	189	204	prostate cancer	T038	UMLS:C0600139
28186998	220	236	European descent	T098	UMLS:C1535514
28186998	263	278	prostate cancer	T038	UMLS:C0600139
28186998	302	320	molecular features	T082	UMLS:C0026383
28186998	324	339	prostate tumors	T038	UMLS:C0033578
28186998	353	359	HOXB13	T017	UMLS:C1415664
28186998	360	373	G84E carriers	T038	UMLS:C0206530
28186998	445	474	heterozygous carriers of G84E	T038	UMLS:C0206530
28186998	489	510	radical prostatectomy	T058	UMLS:C0194810
28186998	515	530	prostate cancer	T038	UMLS:C0600139
28186998	578	582	race	T098	UMLS:C0034510
28186998	592	603	tumor grade	T038	UMLS:C0027651
28186998	610	616	HOXB13	T017	UMLS:C1415664
28186998	617	626	wild-type	T017	UMLS:C1883559
28186998	637	651	Immunostaining	T058	UMLS:C0022885
28186998	656	662	HOXB13	T103	UMLS:C1436058
28186998	664	668	PTEN	T103	UMLS:C1430988
28186998	670	673	ERG	T103	UMLS:C0295291
28186998	675	678	p53	T103	UMLS:C0080055
28186998	683	689	SPINK1	T103	UMLS:C1452174
28186998	701	704	RNA	T103	UMLS:C0035668
28186998	705	726	in situ hybridization	T062	UMLS:C0162788
28186998	731	735	ETV1	T017	UMLS:C1333361
28186998	738	739	4	T017	UMLS:C1333362
28186998	742	743	5	T017	UMLS:C1414477
28186998	765	793	genetically validated assays	T058	UMLS:C0005507
28186998	795	801	Tumors	T038	UMLS:C0027651
28186998	807	820	G84E carriers	T038	UMLS:C0206530
28186998	831	840	expressed	T038	UMLS:C1171362
28186998	841	855	HOXB13 protein	T103	UMLS:C1436058
28186998	892	901	wild-type	T017	UMLS:C1883559
28186998	910	913	ETS	T017	UMLS:C0812380
28186998	914	929	gene expression	T038	UMLS:C0017262
28186998	938	941	ERG	T017	UMLS:C0599295
28186998	945	949	ETV1	T017	UMLS:C1333361
28186998	952	953	4	T017	UMLS:C1333362
28186998	956	957	5	T017	UMLS:C1414477
28186998	987	993	tumors	T038	UMLS:C0027651
28186998	999	1012	G84E carriers	T038	UMLS:C0206530
28186998	1067	1071	PTEN	T103	UMLS:C1430988
28186998	1100	1113	G84E carriers	T038	UMLS:C0206530
28186998	1167	1171	PTEN	T103	UMLS:C1430988
28186998	1196	1199	ERG	T103	UMLS:C0295291
28186998	1202	1210	positive	T033	UMLS:C1446409
28186998	1223	1226	ERG	T103	UMLS:C0295291
28186998	1229	1237	negative	T033	UMLS:C0205160
28186998	1238	1244	tumors	T038	UMLS:C0027651
28186998	1301	1312	p53 protein	T103	UMLS:C0080055
28186998	1339	1343	TP53	T017	UMLS:C0079419
28186998	1344	1362	missense mutations	T038	UMLS:C0599155
28186998	1424	1437	G84E carriers	T038	UMLS:C0206530
28186998	1521	1526	genes	T017	UMLS:C0017337
28186998	1538	1541	ERG	T017	UMLS:C0599295
28186998	1546	1550	PTEN	T017	UMLS:C0694888
28186998	1561	1575	carcinogenesis	T038	UMLS:C0596263
28186998	1609	1612	men	T098	UMLS:C0025266
28186998	1618	1643	germline HOXB13 mutations	T038	UMLS:C0206530